Unknown

Dataset Information

0

Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.


ABSTRACT: Glioblastoma is frequently associated with TP53 mutation, which is linked to a worse prognosis and response to conventional treatments (chemoradiotherapy). Therefore, targeting TP53 is a promising strategy to overcome this poor therapeutic response. Tumor-treating fields (TTFields) are a recently approved treatment for newly diagnosed glioblastoma, which involves direct application of low-intensity, intermediate-frequency alternating electric fields to the tumor, thereby offering a local tumor-killing effect. However, the influence of TP53 mutation status on the effectiveness of TTFields is controversial. Here, we identified the key gene signatures and pathways associated with TTFields in four glioblastoma cell lines varying in TP53 mutation status using gene profiling and functional annotation. Overall, genes associated with the cell cycle, cell death, and immune response were significantly altered by TTFields regardless of TP53 status. TTFields appeared to exert enhanced anti-cancer effects by altering the immune system in the inflammatory environment and regulating cell cycle- and cell death-related genes, but the precise genes influenced vary according to TP53 status. These results should facilitate detailed mechanistic studies on the molecular basis of TTFields to further develop this modality as combination therapy, which can improve the therapeutic effect and minimize side effects of chemoradiotherapy.

SUBMITTER: Lee YJ 

PROVIDER: S-EPMC7378235 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.

Lee Yeon-Joo YJ   Seo Hyun Wook HW   Baek Jeong-Hwa JH   Lim Sun Ha SH   Hwang Sang-Gu SG   Kim Eun Ho EH  

Scientific reports 20200723 1


Glioblastoma is frequently associated with TP53 mutation, which is linked to a worse prognosis and response to conventional treatments (chemoradiotherapy). Therefore, targeting TP53 is a promising strategy to overcome this poor therapeutic response. Tumor-treating fields (TTFields) are a recently approved treatment for newly diagnosed glioblastoma, which involves direct application of low-intensity, intermediate-frequency alternating electric fields to the tumor, thereby offering a local tumor-k  ...[more]

Similar Datasets

| S-EPMC10232578 | biostudies-literature
| S-EPMC8085847 | biostudies-literature
| S-EPMC6125382 | biostudies-literature
| S-EPMC9256561 | biostudies-literature
| S-EPMC8363068 | biostudies-literature
| S-EPMC9913762 | biostudies-literature
| S-EPMC11341748 | biostudies-literature
| S-EPMC9912101 | biostudies-literature
| S-EPMC8833244 | biostudies-literature
| S-EPMC10462574 | biostudies-literature